Loading
A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration is a phase 1/2 interventional study registered as NCT06973564 by Jacobio Pharmaceuticals Co., Ltd., with 294 participants planned, started 2025-05-29 and due to reach its primary completion in 2027-11. Interventions recorded: JAB-23E73.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/